Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
15.96 USD
↗ 0.02 (0.13%)AT CLOSE (11:59 AM EDT)
16.08
↗ 0.11 (0.72%)
POST MARKET (AS OF 07:19 PM EDT)
Post Market
AS OF 07:19 PM EDT
16.08
↗ 0.11 (0.72%)
🔴Market: CLOSED

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $15.97. The stock presents a mixed profile: our models indicate a Buy for underlying fundamentals, while technical indicators flash a Sell. Notable factors include a robust Altman Z-Score, exceptional Return on Equity (52.5%) and a bullish Golden Cross on the moving averages. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Jul 17, 2026.

Open?$15.69
High?$16.19
Low?$15.66
Prev. Close?$15.94
Volume?789.0K
Avg. Volume?1.8M
VWAP?$16.00
Rel. Volume?0.44x
Bid / Ask
Bid?$13.80 × 100
Ask?$18.46 × 100
Spread?$4.66
Midpoint?$16.13
Valuation & Ratios
Market Cap?2.0B
Shares Out?128.6M
Float?103.0M
Float %?79.2%
P/E Ratio?6.88
P/B Ratio?3.61
EPS?$2.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
100
Momentum?
73
Short Sent.?
40
Piotroski F-Score?6/9Mixed
Altman Z-Score?8.25Safe
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.31%Elevated
Short Interest?9.6M
Days to Cover?3.9
Free Float103.0M
Avg Daily Volume2.5M
Settlement Date2026-06-30
Financial Health
Current Ratio?5.55Strong
Quick Ratio?5.01Strong
Cash Ratio?0.47Low
Debt/Equity?0.11Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
97
6.9CHEAP▾
P/B?
Peers
100
S&P
48
3.61FAIR▾
P/S?
Peers
100
S&P
18
6.87FAIR▾
P/FCF?
Peers
100
S&P
82
12.3CHEAP▾
EV/EBITDA?
Peers
100
S&P
44
15.9FAIR▾
EV/Sales?
Peers
100
S&P
20
6.95HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
52.5%STRONG▾
ROA?
Peers
50
S&P
97
41.2%STRONG▾
Cash Flow & Enterprise
FCF?$166.6M
Enterprise Value?$2.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist